ImmunityBio, Inc.
NASDAQ Global SelectTotal Valuation
ImmunityBio, Inc. carries a market capitalization of 7.67B, placing it among publicly traded companies globally. Its enterprise value stands at 7.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.67B |
| Enterprise Value | 7.72B |
Share Statistics
ImmunityBio, Inc. currently has 1.05B shares outstanding.
| Shares Outstanding | 1.05B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 52.38, and the price-to-book ratio stands at -1.69.
| PE Ratio | N/A |
| PS Ratio | 52.38 |
| PB Ratio | -1.69 |
| P/TBV Ratio | -8.37 |
| P/FCF Ratio | -25.51 |
| P/OCF Ratio | -25.09 |
Enterprise Valuation
| EV / Sales | 54.79 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
ImmunityBio, Inc. maintains a current ratio of 6.67, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -82.75, indicating conservative leverage, while an interest coverage ratio of -2.19 demonstrates limited ability to service its debt obligations.
| Current Ratio | 6.67 |
| Quick Ratio | 6.24 |
| Debt / Equity | -82.75 |
| Debt / EBITDA | -2.93 |
| Interest Coverage | -2.19 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -179.83 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.21 |
Taxes
| Income Tax | 108,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
ImmunityBio, Inc.'s stock has gained approximately 165.21739% over the past 52 weeks. The 50-day moving average sits at 7.55, while the 200-day moving average is 5.16.
| Beta (5Y) | N/A |
| 52-Week Price Change | 165.21739% |
| 50-Day Moving Average | 7.55 |
| 200-Day Moving Average | 5.16 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, ImmunityBio, Inc. generated 140.98M in revenue and converted that into -854.53M in net income, yielding earnings per share of -0.89. EBITDA reached -245.31M, while operating income came in at -261.39M.
| Revenue | 140.98M |
| Gross Profit | 140.04M |
| Operating Income | -261.39M |
| Pretax Income | -854.49M |
| Net Income | -854.53M |
| EBITDA | -245.31M |
| EBIT | -261.39M |
| Earnings Per Share (EPS) | -0.89 |
Balance Sheet
ImmunityBio, Inc. holds 380.88M in cash and equivalents against 719.16M in total debt, resulting in a net debt position of 473.19M. Total book value stands at -4.36B, with working capital of 385.00M providing operational flexibility.
| Cash & Cash Equivalents | 380.88M |
| Total Debt | 719.16M |
| Net Debt | 473.19M |
| Equity (Book Value) | -4.36B |
| Book Value Per Share | -4.53 |
| Working Capital | 385.00M |
Cash Flow
ImmunityBio, Inc. produced -294.39M in operating cash flow over the past twelve months. After subtracting -4.88M in capital expenditures, free cash flow totaled -299.27M - equivalent to -0.31 per share.
| Operating Cash Flow | -294.39M |
| Capital Expenditures | -4.88M |
| Free Cash Flow | -299.27M |
| FCF Per Share | -0.31 |
Margins
ImmunityBio, Inc. operates with a gross margin of 99.34, reflecting its pricing power and cost economics. The operating margin of -185.41 and net profit margin of -606.15 provide insight into operational efficiency.
| Gross Margin | 99.34 |
| Operating Margin | -185.41 |
| Pretax Margin | -606.12 |
| Profit Margin | -606.15 |
| EBITDA Margin | -174.01 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -8.47 |
| FCF Yield | -3.92 |
Scores
ImmunityBio, Inc. posts an Altman Z-Score of -7.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.12 |